Jonathan Gelfond

EBioMedicine 2023

Open access · CC-BY

Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerability

▲ 297

Aging Cell 2019

Open access · CC-BY

Acarbose improves health and lifespan in aging HET3 mice

▲ 142

Aging Cell 2015

Open access · CC-BY

Chronic mTOR inhibition in mice with rapamycin alters T , B , myeloid, and innate lymphoid cells and gut flora and prolongs life of immune‐deficient mice

▲ 128

Aging Cell 2011

Open access · OA

Fat maintenance is a predictor of the murine lifespan response to dietary restriction

▲ 125

PLoS ONE 2015

Open access · CC0

Health Effects of Long-Term Rapamycin Treatment: The Impact on Mouse Health of Enteric Rapamycin Treatment from Four Months of Age throughout Life

▲ 75

Aging 2016

Open access · CC-BY

A cross-sectional study of male and female C57BL/6Nia mice suggests lifespan and healthspan are not necessarily correlated

▲ 70

Aging Cell 2022

Open access · CC-BY

Lifespan benefits for the combination of rapamycin plus acarbose and for captopril in genetically heterogeneous mice

▲ 67

Aging Cell 2013

Open access · CC-BY

Combined treatment of rapamycin and dietary restriction has a larger effect on the transcriptome and metabolome of liver

▲ 62

GeroScience 2023

Preprint · OA

A randomized placebo-controlled trial of nicotinamide riboside in older adults with mild cognitive impairment

▲ 55

Cell Stress and Chaperones 2016

Open access · CC-BY

Determinants of rodent longevity in the chaperone-protein degradation network

▲ 42

GeroScience 2024

Open access · CC-BY

The Gehan test identifies life-extending compounds overlooked by the log-rank test in the NIA Interventions Testing Program: Metformin, Enalapril, caffeic acid phenethyl ester, green tea extract, and 17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride

▲ 10

Nature Communications 2025

Open access · CC-BY

Deciphering the timing and impact of life-extending interventions: temporal efficacy profiler distinguishes early, midlife, and senescence phase efficacies

▲ 7

bioRxiv (Cold Spring Harbor Laboratory) 2024

Preprint · CC-BY

Deciphering the Timing and Impact of Life-extending Interventions: Temporal Efficacy Profiler Distinguishes Early, Midlife, and Senescence Phase Efficacies

▲ 2

The Journals of Gerontology Series A 2025

Open access · OA

Sex as a major determinant of pro-longevity drug efficacy: a review of two decades of the NIA Interventions Testing Program

▲ 2

European Respiratory Journal 2023

Citation only

Post hoc pooled analyses of open-label and randomized controlled trials of senolytics dasatinib and quercetin in Idiopathic Pulmonary Fibrosis

▲ 1

Statistical Applications in Genetics and Molecular Biology 2015

Citation only

Homology cluster differential expression analysis for interspecies mRNA-Seq experiments

▲ 1

Collaborators

Works in the record

Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerability

Acarbose improves health and lifespan in aging HET3 mice

Chronic mTOR inhibition in mice with rapamycin alters T , B , myeloid, and innate lymphoid cells and gut flora and prolongs life of immune‐deficient mice

Fat maintenance is a predictor of the murine lifespan response to dietary restriction

Health Effects of Long-Term Rapamycin Treatment: The Impact on Mouse Health of Enteric Rapamycin Treatment from Four Months of Age throughout Life

A cross-sectional study of male and female C57BL/6Nia mice suggests lifespan and healthspan are not necessarily correlated

Lifespan benefits for the combination of rapamycin plus acarbose and for captopril in genetically heterogeneous mice

Combined treatment of rapamycin and dietary restriction has a larger effect on the transcriptome and metabolome of liver

A randomized placebo-controlled trial of nicotinamide riboside in older adults with mild cognitive impairment

Determinants of rodent longevity in the chaperone-protein degradation network

The Gehan test identifies life-extending compounds overlooked by the log-rank test in the NIA Interventions Testing Program: Metformin, Enalapril, caffeic acid phenethyl ester, green tea extract, and 17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride

Deciphering the timing and impact of life-extending interventions: temporal efficacy profiler distinguishes early, midlife, and senescence phase efficacies

Deciphering the Timing and Impact of Life-extending Interventions: Temporal Efficacy Profiler Distinguishes Early, Midlife, and Senescence Phase Efficacies

Sex as a major determinant of pro-longevity drug efficacy: a review of two decades of the NIA Interventions Testing Program

Post hoc pooled analyses of open-label and randomized controlled trials of senolytics dasatinib and quercetin in Idiopathic Pulmonary Fibrosis

Homology cluster differential expression analysis for interspecies mRNA-Seq experiments